Gsa Capital Partners LLP Meridian Bioscience Inc Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 12, 2020	SELL	$5.57 - $11.5 $227,222 - $469,131	-40,794 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$7.9 - $10.14 $61,193 - $78,544	-7,746 Reduced 15.96%	40,794 $399,000
Q3 2019 Nov 12, 2019	SELL	$9.17 - $12.01 $30,187 - $39,536	-3,292 Reduced 6.35%	48,540 $461,000
Q2 2019 Aug 06, 2019	BUY	$10.88 - $17.6 $563,932 - $912,243	51,832 New	51,832 $616,000
Q1 2019 May 15, 2019	SELL	$15.51 - $17.61 $245,445 - $278,678	-15,825 Closed	0 $0
Q4 2018 Feb 12, 2019	SELL	$14.52 - $19.72 $1.58 Million - $2.15 Million	-108,967 Reduced 87.32%	15,825 $275,000
Q3 2018 Nov 13, 2018	SELL	$14.85 - $16.35 $222,081 - $244,514	-14,955 Reduced 10.7%	124,792 $1.86 Million
Q2 2018 Aug 09, 2018	SELL	$13.8 - $16.8 $247,585 - $301,408	-17,941 Reduced 11.38%	139,747 $2.22 Million
Q1 2018 May 11, 2018	BUY	$13.8 - $16.2 $922,364 - $1.08 Million	66,838 Added 73.57%	157,688 $2.24 Million
Q4 2017 Feb 14, 2018	SELL	$13.55 - $15.8 $277,327 - $323,378	-20,467 Reduced 18.39%	90,850 $1.27 Million
Q3 2017 Nov 20, 2017	BUY	$13.45 - $14.35 $1.5 Million - $1.6 Million	111,317	111,317 $1.59 Million

113K

Ticker VIVO
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 43,748,000
Description
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.